Nanobiotix (NASDAQ:NBTX) Shares Down 7.5% – Time to Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price was down 7.5% on Monday. The company traded as low as $28.60 and last traded at $29.0160. 18,215 shares traded hands during trading, a decline of 81% from the average session volume of 95,396 shares. The stock had previously closed at $31.37.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Guggenheim initiated coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Nanobiotix presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Nanobiotix Stock Down 8.2%

The firm’s 50-day simple moving average is $32.53 and its 200 day simple moving average is $33.73.

Nanobiotix Company Profile

Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.

Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors.